Blood-based biomarkers represent a less invasive and potentially cheaper approach for
aiding Alzheimer's disease (AD) detection compared with cerebrospinal fluid and some …

Blood-circulating biomarkers have the potential to detect Alzheimer's disease (AD)
pathology before clinical symptoms emerge and to improve the outcomes of clinical trials for …

Alzheimer's disease (AD) is the most common cause of dementia among elderly population.
Deranged β-amyloid (Aβ) trafficking across the blood–brain barrier is known to be a critical …

As genome-wide association studies (GWAS) have grown in size, the number of genetic
variants that have been associated per disease has correspondingly increased. Despite this …

Alzheimer's disease (AD) is a chronic progressive neurodegenerative disease that affects
the quality of life of elderly individuals, while the pathogenesis of AD is still unclear. Based …

Memory decline is common in elderly individuals and is the hallmark of Alzheimer's disease
(AD). Memory failure follows the loss of synaptic contacts in the cerebral cortex and …

Simple Summary Fear extinction is the driving mechanism to reduce the fear response, and
it is the basis of exposure-based cognitive-behavioral therapy. Butyrylcholinesterase (BChE) …

Background: Because dementia is an emerging problem in the world, biochemical markers
of cerebrospinal fluid (CSF) and radio-isotopic analyses are helpful for diagnosing …

In Alzheimer's disease, the transporter P-glycoprotein is responsible for the clearance of
amyloid-β in the brain. Amyloid-β correlates with the sphingomyelin metabolism, and …

Background: Copy number variations (CNVs) play an important role in the genetic etiology
of various neurological disorders, including Alzheimer's disease (AD). Type 2 diabetes …